vs

Side-by-side financial comparison of Metallus Inc. (MTUS) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Metallus Inc. is the larger business by last-quarter revenue ($267.3M vs $207.3M, roughly 1.3× Ultragenyx Pharmaceutical Inc.). Metallus Inc. runs the higher net margin — -5.3% vs -62.0%, a 56.7% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 11.1%). Metallus Inc. produced more free cash flow last quarter ($-37.2M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs -8.8%).

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

MTUS vs RARE — Head-to-Head

Bigger by revenue
MTUS
MTUS
1.3× larger
MTUS
$267.3M
$207.3M
RARE
Growing faster (revenue YoY)
RARE
RARE
+14.7% gap
RARE
25.9%
11.1%
MTUS
Higher net margin
MTUS
MTUS
56.7% more per $
MTUS
-5.3%
-62.0%
RARE
More free cash flow
MTUS
MTUS
$63.6M more FCF
MTUS
$-37.2M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
-8.8%
MTUS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MTUS
MTUS
RARE
RARE
Revenue
$267.3M
$207.3M
Net Profit
$-14.3M
$-128.6M
Gross Margin
2.2%
Operating Margin
-7.7%
-54.7%
Net Margin
-5.3%
-62.0%
Revenue YoY
11.1%
25.9%
Net Profit YoY
33.2%
3.5%
EPS (diluted)
$-0.34
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MTUS
MTUS
RARE
RARE
Q4 25
$267.3M
$207.3M
Q3 25
$305.9M
$159.9M
Q2 25
$304.6M
$166.5M
Q1 25
$280.5M
$139.3M
Q4 24
$240.5M
$164.6M
Q3 24
$227.2M
$139.5M
Q2 24
$294.7M
$147.0M
Q1 24
$321.6M
$108.8M
Net Profit
MTUS
MTUS
RARE
RARE
Q4 25
$-14.3M
$-128.6M
Q3 25
$8.1M
$-180.4M
Q2 25
$3.7M
$-115.0M
Q1 25
$1.3M
$-151.1M
Q4 24
$-21.4M
$-133.2M
Q3 24
$-5.9M
$-133.5M
Q2 24
$4.6M
$-131.6M
Q1 24
$24.0M
$-170.7M
Gross Margin
MTUS
MTUS
RARE
RARE
Q4 25
2.2%
Q3 25
11.4%
Q2 25
10.6%
Q1 25
7.8%
Q4 24
4.5%
Q3 24
5.3%
Q2 24
8.2%
Q1 24
15.7%
Operating Margin
MTUS
MTUS
RARE
RARE
Q4 25
-7.7%
-54.7%
Q3 25
3.6%
-106.9%
Q2 25
2.8%
-64.8%
Q1 25
1.0%
-102.6%
Q4 24
-10.1%
-74.3%
Q3 24
-3.1%
-94.6%
Q2 24
2.1%
-79.1%
Q1 24
9.3%
-151.9%
Net Margin
MTUS
MTUS
RARE
RARE
Q4 25
-5.3%
-62.0%
Q3 25
2.6%
-112.8%
Q2 25
1.2%
-69.0%
Q1 25
0.5%
-108.5%
Q4 24
-8.9%
-80.9%
Q3 24
-2.6%
-95.7%
Q2 24
1.6%
-89.5%
Q1 24
7.5%
-156.8%
EPS (diluted)
MTUS
MTUS
RARE
RARE
Q4 25
$-0.34
$-1.28
Q3 25
$0.19
$-1.81
Q2 25
$0.09
$-1.17
Q1 25
$0.03
$-1.57
Q4 24
$-0.46
$-1.34
Q3 24
$-0.13
$-1.40
Q2 24
$0.10
$-1.52
Q1 24
$0.52
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MTUS
MTUS
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$156.7M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$686.0M
$-80.0M
Total Assets
$1.1B
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MTUS
MTUS
RARE
RARE
Q4 25
$156.7M
$421.0M
Q3 25
$191.5M
$202.5M
Q2 25
$190.8M
$176.3M
Q1 25
$180.3M
$127.1M
Q4 24
$240.7M
$174.0M
Q3 24
$254.6M
$150.6M
Q2 24
$272.8M
$480.7M
Q1 24
$278.1M
$112.3M
Total Debt
MTUS
MTUS
RARE
RARE
Q4 25
Q3 25
$0
Q2 25
$0
Q1 25
$5.4M
Q4 24
$5.4M
Q3 24
$13.2M
Q2 24
$13.2M
Q1 24
$13.2M
Stockholders' Equity
MTUS
MTUS
RARE
RARE
Q4 25
$686.0M
$-80.0M
Q3 25
$697.7M
$9.2M
Q2 25
$690.0M
$151.3M
Q1 25
$686.1M
$144.2M
Q4 24
$690.5M
$255.0M
Q3 24
$712.7M
$346.8M
Q2 24
$736.3M
$432.4M
Q1 24
$739.3M
$140.3M
Total Assets
MTUS
MTUS
RARE
RARE
Q4 25
$1.1B
$1.5B
Q3 25
$1.2B
$1.2B
Q2 25
$1.1B
$1.3B
Q1 25
$1.1B
$1.3B
Q4 24
$1.1B
$1.5B
Q3 24
$1.1B
$1.5B
Q2 24
$1.1B
$1.6B
Q1 24
$1.2B
$1.3B
Debt / Equity
MTUS
MTUS
RARE
RARE
Q4 25
Q3 25
0.00×
Q2 25
0.00×
Q1 25
0.01×
Q4 24
0.01×
Q3 24
0.02×
Q2 24
0.02×
Q1 24
0.02×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MTUS
MTUS
RARE
RARE
Operating Cash FlowLast quarter
$-1.9M
$-99.8M
Free Cash FlowOCF − Capex
$-37.2M
$-100.8M
FCF MarginFCF / Revenue
-13.9%
-48.6%
Capex IntensityCapex / Revenue
13.2%
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-93.0M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MTUS
MTUS
RARE
RARE
Q4 25
$-1.9M
$-99.8M
Q3 25
$22.0M
$-91.4M
Q2 25
$34.8M
$-108.3M
Q1 25
$-38.9M
$-166.5M
Q4 24
$13.9M
$-79.3M
Q3 24
$-15.3M
$-67.0M
Q2 24
$8.3M
$-77.0M
Q1 24
$33.4M
$-190.7M
Free Cash Flow
MTUS
MTUS
RARE
RARE
Q4 25
$-37.2M
$-100.8M
Q3 25
$-6.4M
$-92.7M
Q2 25
$17.0M
$-110.7M
Q1 25
$-66.4M
$-167.8M
Q4 24
$-1.3M
$-79.5M
Q3 24
$-32.9M
$-68.6M
Q2 24
$-5.8M
$-79.0M
Q1 24
$16.0M
$-193.9M
FCF Margin
MTUS
MTUS
RARE
RARE
Q4 25
-13.9%
-48.6%
Q3 25
-2.1%
-58.0%
Q2 25
5.6%
-66.5%
Q1 25
-23.7%
-120.5%
Q4 24
-0.5%
-48.3%
Q3 24
-14.5%
-49.2%
Q2 24
-2.0%
-53.7%
Q1 24
5.0%
-178.2%
Capex Intensity
MTUS
MTUS
RARE
RARE
Q4 25
13.2%
0.5%
Q3 25
9.3%
0.8%
Q2 25
5.8%
1.5%
Q1 25
9.8%
1.0%
Q4 24
6.3%
0.1%
Q3 24
7.7%
1.2%
Q2 24
4.8%
1.4%
Q1 24
5.4%
3.0%
Cash Conversion
MTUS
MTUS
RARE
RARE
Q4 25
Q3 25
2.72×
Q2 25
9.41×
Q1 25
-29.92×
Q4 24
Q3 24
Q2 24
1.80×
Q1 24
1.39×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MTUS
MTUS

Industrial Market Sector$95.3M36%
Manufactured Components$67.8M25%
Aerospace And Defense$39.6M15%
Seamless Mechanical Tubing$31.3M12%
Energy Market Sector$18.3M7%
Other$11.3M4%
Other Market Sector$3.7M1%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons